Validation pour Ingenuity236

vers la météo de la validation par utilisateur

Ingenuity236

precedent - 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 - suivant

Phrase 15 - PMID ?

In Hela cells treated with cycloheximide and with zVAD FMK and overproducing SP NODE protein , agonist anti SP Apo 1 [NODE] protein antibody in cell culture increases ( in a dose dependent manner ) production of SP NODE protein .

Non annotée
Je ne sais pas
Je n'ai pas trouvé d'analyse satisfaisante

Commentaires :

Analyse 0

                  +----------------------------COMP:V-N(with)----------------------------+       +-----------APPOS-----------+                           +--------SUBJ:V-N--------+---------COMP:V-N(in)---------+          +--------COMP:N-N(of)-------+     
      +COMP:V-N(In+------------COMP:V-N(with)------------+            +---MOD_ATT:N-ADJ--+       |         +-MOD_ATT:N-N+    |         +---MOD_ATT:N-N---+--COMP:N-N(in)-+        |              +--MOD_ATT:N-N--+          |           +-MOD_ATT:N-ADJ-+     
      |    +SUBJ:V+-COMP:V-N(with)+                  +MOD+            |          +MOD_ATT+       |         |      +MOD_A+MOD_+         |        +MOD_ATT:+         +MOD_A+        |              |      +MOD_ATT:+          |           |       +MOD_ATT+     
      |    |      |               |                  |   |            |          |       |       |         |      |     |    |         |        |        |         |     |        |              |      |        |          |           |       |       |     
 In Hela cells treated with cycloheximide and with zVAD FMK and overproducing __SP__ __NODE__ protein , agonist anti __SP__ Apo 1 [__NODE__] protein antibody in cell culture increases ( in a dose dependent manner ) production of __SP__ __NODE__ protein .
COMP:V-N(In) (treat,Hela)
SUBJ:V-N (treat,cell)
COMP:V-N(with) (treat,cycloheximide)
COMP:V-N(with) (treat,FMK)
COMP:V-N(with) (treat,__NODE__)
MOD_ATT:N-ADJ (FMK,zVAD)
MOD_ATT:N-ADJ (__NODE__,overproduce)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (protein,Apo)
MOD_ATT:N-N (__SP__,agonist)
MOD_ATT:N-N (__SP__,anti)
MOD_ATT:N-N (Apo,__SP__)
MOD_ATT:N-N (antibody,[__NODE__])
MOD_ATT:N-N (antibody,protein)
COMP:N-N(in) (antibody,culture)
MOD_ATT:N-N (culture,cell)
SUBJ:V-N (increase,antibody)
COMP:V-N(in) (increase,manner)
MOD_ATT:N-N (manner,dose)
MOD_ATT:N-ADJ (manner,dependent)
COMP:N-N(of) (production,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)

Analyse 1

                  +------------------------COMP:V-N(with)------------------------+               +-----------APPOS-----------+                           +------COMP:N-N(in)------+                                         +--------COMP:N-N(of)-------+     
      +COMP:V-N(In+------------COMP:V-N(with)------------+                       |               |         +-MOD_ATT:N-N+    |         +---MOD_ATT:N-N---+         +--MOD_ATT:N-N-+              +--MOD_ATT:N-N--+          |           +-MOD_ATT:N-ADJ-+     
      |    +SUBJ:V+-COMP:V-N(with)+                  +MOD+            +MOD_ATT:N-+       +MOD_ATT+         |      +MOD_A+MOD_+         |        +MOD_ATT:+         |     +MOD_ATT:+              |      +MOD_ATT:+          |           |       +MOD_ATT+     
      |    |      |               |                  |   |            |          |       |       |         |      |     |    |         |        |        |         |     |        |              |      |        |          |           |       |       |     
 In Hela cells treated with cycloheximide and with zVAD FMK and overproducing __SP__ __NODE__ protein , agonist anti __SP__ Apo 1 [__NODE__] protein antibody in cell culture increases ( in a dose dependent manner ) production of __SP__ __NODE__ protein .
COMP:V-N(In) (treat,Hela)
SUBJ:V-N (treat,cell)
COMP:V-N(with) (treat,cycloheximide)
COMP:V-N(with) (treat,FMK)
COMP:V-N(with) (treat,__SP__)
MOD_ATT:N-ADJ (FMK,zVAD)
MOD_ATT:N-ADJ (__SP__,overproduce)
MOD_ATT:N-ADJ (protein,__NODE__)
APPOS (protein,Apo)
MOD_ATT:N-N (__SP__,agonist)
MOD_ATT:N-N (__SP__,anti)
MOD_ATT:N-N (Apo,__SP__)
MOD_ATT:N-N (antibody,[__NODE__])
MOD_ATT:N-N (antibody,protein)
COMP:N-N(in) (antibody,increase)
MOD_ATT:N-N (increase,cell)
MOD_ATT:N-N (increase,culture)
MOD_ATT:N-N (manner,dose)
MOD_ATT:N-N (manner,dependent)
COMP:N-N(of) (production,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)

Analyse 2

                  +------------------------COMP:V-N(with)------------------------+                                                                                                                                                                            
                  |                                  +-------MOD_ATT:N-ADJ-------+               +-----------APPOS-----------+                           +------COMP:N-N(in)------+                                         +--------COMP:N-N(of)-------+     
      +COMP:V-N(In+                                  |   +------MOD_ATT:N-N------+               |         +-MOD_ATT:N-N+    |         +---MOD_ATT:N-N---+         +--MOD_ATT:N-N-+              +--MOD_ATT:N-N--+          |           +-MOD_ATT:N-ADJ-+     
      |    +SUBJ:V+-COMP:V-N(with)+                  |   |            +MOD_ATT:N-+       +MOD_ATT+         |      +MOD_A+MOD_+         |        +MOD_ATT:+         |     +MOD_ATT:+              |      +MOD_ATT:+          |           |       +MOD_ATT+     
      |    |      |               |                  |   |            |          |       |       |         |      |     |    |         |        |        |         |     |        |              |      |        |          |           |       |       |     
 In Hela cells treated with cycloheximide and with zVAD FMK and overproducing __SP__ __NODE__ protein , agonist anti __SP__ Apo 1 [__NODE__] protein antibody in cell culture increases ( in a dose dependent manner ) production of __SP__ __NODE__ protein .
COMP:V-N(In) (treat,Hela)
SUBJ:V-N (treat,cell)
COMP:V-N(with) (treat,cycloheximide)
COMP:V-N(with) (treat,__SP__)
MOD_ATT:N-ADJ (__SP__,zVAD)
MOD_ATT:N-N (__SP__,FMK)
MOD_ATT:N-N (__SP__,overproduce)
MOD_ATT:N-ADJ (protein,__NODE__)
APPOS (protein,Apo)
MOD_ATT:N-N (__SP__,agonist)
MOD_ATT:N-N (__SP__,anti)
MOD_ATT:N-N (Apo,__SP__)
MOD_ATT:N-N (antibody,[__NODE__])
MOD_ATT:N-N (antibody,protein)
COMP:N-N(in) (antibody,increase)
MOD_ATT:N-N (increase,cell)
MOD_ATT:N-N (increase,culture)
MOD_ATT:N-N (manner,dose)
MOD_ATT:N-N (manner,dependent)
COMP:N-N(of) (production,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)

Analyse 3

                  +----------------------------COMP:V-N(with)----------------------------+       +-----------APPOS-----------+                           +------COMP:N-N(in)------+                                         +--------COMP:N-N(of)-------+     
      +COMP:V-N(In+------------COMP:V-N(with)------------+            +---MOD_ATT:N-ADJ--+       |         +-MOD_ATT:N-N+    |         +---MOD_ATT:N-N---+         +--MOD_ATT:N-N-+              +--MOD_ATT:N-N--+          |           +-MOD_ATT:N-ADJ-+     
      |    +SUBJ:V+-COMP:V-N(with)+                  +MOD+            |          +MOD_ATT+       |         |      +MOD_A+MOD_+         |        +MOD_ATT:+         |     +MOD_ATT:+              |      +MOD_ATT:+          |           |       +MOD_ATT+     
      |    |      |               |                  |   |            |          |       |       |         |      |     |    |         |        |        |         |     |        |              |      |        |          |           |       |       |     
 In Hela cells treated with cycloheximide and with zVAD FMK and overproducing __SP__ __NODE__ protein , agonist anti __SP__ Apo 1 [__NODE__] protein antibody in cell culture increases ( in a dose dependent manner ) production of __SP__ __NODE__ protein .
COMP:V-N(In) (treat,Hela)
SUBJ:V-N (treat,cell)
COMP:V-N(with) (treat,cycloheximide)
COMP:V-N(with) (treat,FMK)
COMP:V-N(with) (treat,__NODE__)
MOD_ATT:N-ADJ (FMK,zVAD)
MOD_ATT:N-ADJ (__NODE__,overproduce)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (protein,Apo)
MOD_ATT:N-N (__SP__,agonist)
MOD_ATT:N-N (__SP__,anti)
MOD_ATT:N-N (Apo,__SP__)
MOD_ATT:N-N (antibody,[__NODE__])
MOD_ATT:N-N (antibody,protein)
COMP:N-N(in) (antibody,increase)
MOD_ATT:N-N (increase,cell)
MOD_ATT:N-N (increase,culture)
MOD_ATT:N-N (manner,dose)
MOD_ATT:N-N (manner,dependent)
COMP:N-N(of) (production,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)

Analyse 4

                  +-------------------COMP:V-N(with)------------------+                                                                                                                                                                                       
                  +------------COMP:V-N(with)------------+            |                          +-----------APPOS-----------+                           +--------SUBJ:V-N--------+---------COMP:V-N(in)---------+          +--------COMP:N-N(of)-------+     
      +COMP:V-N(In+                                  +--MOD_ATT:N-ADJ-+          +-MOD_ATT:N-ADJ-+         +-MOD_ATT:N-N+    |         +---MOD_ATT:N-N---+--COMP:N-N(in)-+        |              +--MOD_ATT:N-N--+          |           +-MOD_ATT:N-ADJ-+     
      |    +SUBJ:V+-COMP:V-N(with)+                  +MOD+            |          |       +MOD_ATT+         |      +MOD_A+MOD_+         |        +MOD_ATT:+         +MOD_A+        |              |      +MOD_ATT:+          |           |       +MOD_ATT+     
      |    |      |               |                  |   |            |          |       |       |         |      |     |    |         |        |        |         |     |        |              |      |        |          |           |       |       |     
 In Hela cells treated with cycloheximide and with zVAD FMK and overproducing __SP__ __NODE__ protein , agonist anti __SP__ Apo 1 [__NODE__] protein antibody in cell culture increases ( in a dose dependent manner ) production of __SP__ __NODE__ protein .
COMP:V-N(In) (treat,Hela)
SUBJ:V-N (treat,cell)
COMP:V-N(with) (treat,cycloheximide)
COMP:V-N(with) (treat,FMK)
COMP:V-N(with) (treat,overproduce)
MOD_ATT:N-ADJ (FMK,zVAD)
MOD_ATT:N-ADJ (overproduce,zVAD)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
APPOS (protein,Apo)
MOD_ATT:N-N (__SP__,agonist)
MOD_ATT:N-N (__SP__,anti)
MOD_ATT:N-N (Apo,__SP__)
MOD_ATT:N-N (antibody,[__NODE__])
MOD_ATT:N-N (antibody,protein)
COMP:N-N(in) (antibody,culture)
MOD_ATT:N-N (culture,cell)
SUBJ:V-N (increase,antibody)
COMP:V-N(in) (increase,manner)
MOD_ATT:N-N (manner,dose)
MOD_ATT:N-N (manner,dependent)
COMP:N-N(of) (production,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)

Analyse 5

                  +------------------------COMP:V-N(with)------------------------+                                                                                                                                                                            
                  |                                  +-------MOD_ATT:N-ADJ-------+               +-----------APPOS-----------+                           +------COMP:N-N(in)------+                                         +--------COMP:N-N(of)-------+     
      +COMP:V-N(In+                                  |   +------MOD_ATT:N-N------+               |         +-MOD_ATT:N-N+    |         +---MOD_ATT:N-N---+         +--MOD_ATT:N-N-+              +--MOD_ATT:N-N--+          |           +-MOD_ATT:N-ADJ-+     
      |    +SUBJ:V+-COMP:V-N(with)+                  |   |            +MOD_ATT:N-+       +MOD_ATT+         |      +MOD_A+MOD_+         |        +MOD_ATT:+         |     +MOD_ATT:+              |      +MOD_ATT:+          |           |       +MOD_ATT+     
      |    |      |               |                  |   |            |          |       |       |         |      |     |    |         |        |        |         |     |        |              |      |        |          |           |       |       |     
 In Hela cells treated with cycloheximide and with zVAD FMK and overproducing __SP__ __NODE__ protein , agonist anti __SP__ Apo 1 [__NODE__] protein antibody in cell culture increases ( in a dose dependent manner ) production of __SP__ __NODE__ protein .
COMP:V-N(In) (treat,Hela)
SUBJ:V-N (treat,cell)
COMP:V-N(with) (treat,cycloheximide)
COMP:V-N(with) (treat,__SP__)
MOD_ATT:N-ADJ (__SP__,zVAD)
MOD_ATT:N-N (__SP__,FMK)
MOD_ATT:N-N (__SP__,overproduce)
MOD_ATT:N-ADJ (protein,__NODE__)
APPOS (protein,Apo)
MOD_ATT:N-N (__SP__,agonist)
MOD_ATT:N-N (__SP__,anti)
MOD_ATT:N-N (Apo,__SP__)
MOD_ATT:N-N (antibody,[__NODE__])
MOD_ATT:N-N (antibody,protein)
COMP:N-N(in) (antibody,increase)
MOD_ATT:N-N (increase,cell)
MOD_ATT:N-N (increase,culture)
MOD_ATT:N-N (manner,dose)
MOD_ATT:N-ADJ (manner,dependent)
COMP:N-N(of) (production,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)

Analyse 6

                  +-------------------COMP:V-N(with)------------------+                          +-----------APPOS-----------+                           +--------SUBJ:V-N--------+---------COMP:V-N(in)---------+          +--------COMP:N-N(of)-------+     
      +COMP:V-N(In+------------COMP:V-N(with)------------+            |                          |         +-MOD_ATT:N-N+    |         +---MOD_ATT:N-N---+--COMP:N-N(in)-+        |              +--MOD_ATT:N-N--+          |           +-MOD_ATT:N-ADJ-+     
      |    +SUBJ:V+-COMP:V-N(with)+                  +MOD+            |                  +MOD_ATT+         |      +MOD_A+MOD_+         |        +MOD_ATT:+         +MOD_A+        |              |      +MOD_ATT:+          |           |       +MOD_ATT+     
      |    |      |               |                  |   |            |                  |       |         |      |     |    |         |        |        |         |     |        |              |      |        |          |           |       |       |     
 In Hela cells treated with cycloheximide and with zVAD FMK and overproducing __SP__ __NODE__ protein , agonist anti __SP__ Apo 1 [__NODE__] protein antibody in cell culture increases ( in a dose dependent manner ) production of __SP__ __NODE__ protein .
COMP:V-N(In) (treat,Hela)
SUBJ:V-N (treat,cell)
COMP:V-N(with) (treat,cycloheximide)
COMP:V-N(with) (treat,FMK)
COMP:V-N(with) (treat,overproduce)
MOD_ATT:N-ADJ (FMK,zVAD)
MOD_ATT:N-ADJ (protein,__NODE__)
APPOS (protein,Apo)
MOD_ATT:N-N (__SP__,agonist)
MOD_ATT:N-N (__SP__,anti)
MOD_ATT:N-N (Apo,__SP__)
MOD_ATT:N-N (antibody,[__NODE__])
MOD_ATT:N-N (antibody,protein)
COMP:N-N(in) (antibody,culture)
MOD_ATT:N-N (culture,cell)
SUBJ:V-N (increase,antibody)
COMP:V-N(in) (increase,manner)
MOD_ATT:N-N (manner,dose)
MOD_ATT:N-N (manner,dependent)
COMP:N-N(of) (production,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)

Analyse 7

                  +------------------------COMP:V-N(with)------------------------+               +-----------APPOS-----------+                           +------COMP:N-N(in)------+                                         +--------COMP:N-N(of)-------+     
      +COMP:V-N(In+------------COMP:V-N(with)------------+                       |               |         +-MOD_ATT:N-N+    |         +---MOD_ATT:N-N---+         +--MOD_ATT:N-N-+              +--MOD_ATT:N-N--+          |           +-MOD_ATT:N-ADJ-+     
      |    +SUBJ:V+-COMP:V-N(with)+                  +MOD+            +MOD_ATT:N-+               |         |      +MOD_A+MOD_+         |        +MOD_ATT:+         |     +MOD_ATT:+              |      +MOD_ATT:+          |           |       +MOD_ATT+     
      |    |      |               |                  |   |            |          |               |         |      |     |    |         |        |        |         |     |        |              |      |        |          |           |       |       |     
 In Hela cells treated with cycloheximide and with zVAD FMK and overproducing __SP__ __NODE__ protein , agonist anti __SP__ Apo 1 [__NODE__] protein antibody in cell culture increases ( in a dose dependent manner ) production of __SP__ __NODE__ protein .
COMP:V-N(In) (treat,Hela)
SUBJ:V-N (treat,cell)
COMP:V-N(with) (treat,cycloheximide)
COMP:V-N(with) (treat,FMK)
COMP:V-N(with) (treat,__SP__)
MOD_ATT:N-ADJ (FMK,zVAD)
MOD_ATT:N-ADJ (__SP__,overproduce)
APPOS (protein,Apo)
MOD_ATT:N-N (__SP__,agonist)
MOD_ATT:N-N (__SP__,anti)
MOD_ATT:N-N (Apo,__SP__)
MOD_ATT:N-N (antibody,[__NODE__])
MOD_ATT:N-N (antibody,protein)
COMP:N-N(in) (antibody,increase)
MOD_ATT:N-N (increase,cell)
MOD_ATT:N-N (increase,culture)
MOD_ATT:N-N (manner,dose)
MOD_ATT:N-ADJ (manner,dependent)
COMP:N-N(of) (production,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)

Analyse 8

                  +------------------------COMP:V-N(with)------------------------+                                                                                                                                                                            
                  +------------COMP:V-N(with)------------+                       |               +-----------APPOS-----------+                           +------COMP:N-N(in)------+                                         +--------COMP:N-N(of)-------+     
      +COMP:V-N(In+                                  +-------MOD_ATT:N-ADJ-------+               |         +-MOD_ATT:N-N+    |         +---MOD_ATT:N-N---+         +--MOD_ATT:N-N-+              +--MOD_ATT:N-N--+          |           +-MOD_ATT:N-ADJ-+     
      |    +SUBJ:V+-COMP:V-N(with)+                  +MOD+            +MOD_ATT:N-+               |         |      +MOD_A+MOD_+         |        +MOD_ATT:+         |     +MOD_ATT:+              |      +MOD_ATT:+          |           |       +MOD_ATT+     
      |    |      |               |                  |   |            |          |               |         |      |     |    |         |        |        |         |     |        |              |      |        |          |           |       |       |     
 In Hela cells treated with cycloheximide and with zVAD FMK and overproducing __SP__ __NODE__ protein , agonist anti __SP__ Apo 1 [__NODE__] protein antibody in cell culture increases ( in a dose dependent manner ) production of __SP__ __NODE__ protein .
COMP:V-N(In) (treat,Hela)
SUBJ:V-N (treat,cell)
COMP:V-N(with) (treat,cycloheximide)
COMP:V-N(with) (treat,FMK)
COMP:V-N(with) (treat,__SP__)
MOD_ATT:N-ADJ (FMK,zVAD)
MOD_ATT:N-ADJ (__SP__,zVAD)
MOD_ATT:N-N (__SP__,overproduce)
APPOS (protein,Apo)
MOD_ATT:N-N (__SP__,agonist)
MOD_ATT:N-N (__SP__,anti)
MOD_ATT:N-N (Apo,__SP__)
MOD_ATT:N-N (antibody,[__NODE__])
MOD_ATT:N-N (antibody,protein)
COMP:N-N(in) (antibody,increase)
MOD_ATT:N-N (increase,cell)
MOD_ATT:N-N (increase,culture)
MOD_ATT:N-N (manner,dose)
MOD_ATT:N-N (manner,dependent)
COMP:N-N(of) (production,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)

Analyse 9

                  +-------------------COMP:V-N(with)------------------+                                                                                                                                                                                       
                  +------------COMP:V-N(with)------------+            |                          +-----------APPOS-----------+                           +------COMP:N-N(in)------+                                         +--------COMP:N-N(of)-------+     
      +COMP:V-N(In+                                  +--MOD_ATT:N-ADJ-+          +-MOD_ATT:N-ADJ-+         +-MOD_ATT:N-N+    |         +---MOD_ATT:N-N---+         +--MOD_ATT:N-N-+              +--MOD_ATT:N-N--+          |           +-MOD_ATT:N-ADJ-+     
      |    +SUBJ:V+-COMP:V-N(with)+                  +MOD+            |          |       +MOD_ATT+         |      +MOD_A+MOD_+         |        +MOD_ATT:+         |     +MOD_ATT:+              |      +MOD_ATT:+          |           |       +MOD_ATT+     
      |    |      |               |                  |   |            |          |       |       |         |      |     |    |         |        |        |         |     |        |              |      |        |          |           |       |       |     
 In Hela cells treated with cycloheximide and with zVAD FMK and overproducing __SP__ __NODE__ protein , agonist anti __SP__ Apo 1 [__NODE__] protein antibody in cell culture increases ( in a dose dependent manner ) production of __SP__ __NODE__ protein .
COMP:V-N(In) (treat,Hela)
SUBJ:V-N (treat,cell)
COMP:V-N(with) (treat,cycloheximide)
COMP:V-N(with) (treat,FMK)
COMP:V-N(with) (treat,overproduce)
MOD_ATT:N-ADJ (FMK,zVAD)
MOD_ATT:N-ADJ (overproduce,zVAD)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
APPOS (protein,Apo)
MOD_ATT:N-N (__SP__,agonist)
MOD_ATT:N-N (__SP__,anti)
MOD_ATT:N-N (Apo,__SP__)
MOD_ATT:N-N (antibody,[__NODE__])
MOD_ATT:N-N (antibody,protein)
COMP:N-N(in) (antibody,increase)
MOD_ATT:N-N (increase,cell)
MOD_ATT:N-N (increase,culture)
MOD_ATT:N-N (manner,dose)
MOD_ATT:N-N (manner,dependent)
COMP:N-N(of) (production,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)

Analyse 10

                  +------------------------COMP:V-N(with)------------------------+               +-----------APPOS-----------+                           +------COMP:N-N(in)------+                                         +--------COMP:N-N(of)-------+     
      +COMP:V-N(In+------------COMP:V-N(with)------------+                       |               |         +-MOD_ATT:N-N+    |         +---MOD_ATT:N-N---+         +--MOD_ATT:N-N-+              +--MOD_ATT:N-N--+          |           +-MOD_ATT:N-ADJ-+     
      |    +SUBJ:V+-COMP:V-N(with)+                  +MOD+            +MOD_ATT:N-+       +MOD_ATT+         |      +MOD_A+MOD_+         |        +MOD_ATT:+         |     +MOD_ATT:+              |      +MOD_ATT:+          |           |       +MOD_ATT+     
      |    |      |               |                  |   |            |          |       |       |         |      |     |    |         |        |        |         |     |        |              |      |        |          |           |       |       |     
 In Hela cells treated with cycloheximide and with zVAD FMK and overproducing __SP__ __NODE__ protein , agonist anti __SP__ Apo 1 [__NODE__] protein antibody in cell culture increases ( in a dose dependent manner ) production of __SP__ __NODE__ protein .
COMP:V-N(In) (treat,Hela)
SUBJ:V-N (treat,cell)
COMP:V-N(with) (treat,cycloheximide)
COMP:V-N(with) (treat,FMK)
COMP:V-N(with) (treat,__SP__)
MOD_ATT:N-ADJ (FMK,zVAD)
MOD_ATT:N-N (__SP__,overproduce)
MOD_ATT:N-ADJ (protein,__NODE__)
APPOS (protein,Apo)
MOD_ATT:N-N (__SP__,agonist)
MOD_ATT:N-N (__SP__,anti)
MOD_ATT:N-N (Apo,__SP__)
MOD_ATT:N-N (antibody,[__NODE__])
MOD_ATT:N-N (antibody,protein)
COMP:N-N(in) (antibody,increase)
MOD_ATT:N-N (increase,cell)
MOD_ATT:N-N (increase,culture)
MOD_ATT:N-N (manner,dose)
MOD_ATT:N-ADJ (manner,dependent)
COMP:N-N(of) (production,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)

Analyse 11

                  +-------------------COMP:V-N(with)------------------+                          +-----------APPOS-----------+                           +--------SUBJ:V-N--------+---------COMP:V-N(in)---------+          +--------COMP:N-N(of)-------+     
      +COMP:V-N(In+------------COMP:V-N(with)------------+            |                          |         +-MOD_ATT:N-N+    |         +---MOD_ATT:N-N---+--COMP:N-N(in)-+        |              +--MOD_ATT:N-N--+          |           +-MOD_ATT:N-ADJ-+     
      |    +SUBJ:V+-COMP:V-N(with)+                  +MOD+            |                  +MOD_ATT+         |      +MOD_A+MOD_+         |        +MOD_ATT:+         +MOD_A+        |              |      +MOD_ATT:+          |           |       +MOD_ATT+     
      |    |      |               |                  |   |            |                  |       |         |      |     |    |         |        |        |         |     |        |              |      |        |          |           |       |       |     
 In Hela cells treated with cycloheximide and with zVAD FMK and overproducing __SP__ __NODE__ protein , agonist anti __SP__ Apo 1 [__NODE__] protein antibody in cell culture increases ( in a dose dependent manner ) production of __SP__ __NODE__ protein .
COMP:V-N(In) (treat,Hela)
SUBJ:V-N (treat,cell)
COMP:V-N(with) (treat,cycloheximide)
COMP:V-N(with) (treat,FMK)
COMP:V-N(with) (treat,overproduce)
MOD_ATT:N-ADJ (FMK,zVAD)
MOD_ATT:N-ADJ (protein,__NODE__)
APPOS (protein,Apo)
MOD_ATT:N-N (__SP__,agonist)
MOD_ATT:N-N (__SP__,anti)
MOD_ATT:N-N (Apo,__SP__)
MOD_ATT:N-N (antibody,[__NODE__])
MOD_ATT:N-N (antibody,protein)
COMP:N-N(in) (antibody,culture)
MOD_ATT:N-N (culture,cell)
SUBJ:V-N (increase,antibody)
COMP:V-N(in) (increase,manner)
MOD_ATT:N-N (manner,dose)
MOD_ATT:N-ADJ (manner,dependent)
COMP:N-N(of) (production,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)

Analyse 12

                  +------------------------COMP:V-N(with)------------------------+                                                                                                                                                                            
                  |                             +-----------------OBJ:V-N----------------+                                                                                                                                                                    
                  |                             |    +-------MOD_ATT:N-ADJ-------+       |       +-----------APPOS-----------+                           +------COMP:N-N(in)------+                                         +--------COMP:N-N(of)-------+     
      +COMP:V-N(In+                             |    |   +------MOD_ATT:N-N------+       |       |         +-MOD_ATT:N-N+    |         +---MOD_ATT:N-N---+         +--MOD_ATT:N-N-+              +--MOD_ATT:N-N--+          |           +-MOD_ATT:N-ADJ-+     
      |    +SUBJ:V+-COMP:V-N(with)+             |    |   |            +MOD_ATT:N-+       |       |         |      +MOD_A+MOD_+         |        +MOD_ATT:+         |     +MOD_ATT:+              |      +MOD_ATT:+          |           |       +MOD_ATT+     
      |    |      |               |             |    |   |            |          |       |       |         |      |     |    |         |        |        |         |     |        |              |      |        |          |           |       |       |     
 In Hela cells treated with cycloheximide and with zVAD FMK and overproducing __SP__ __NODE__ protein , agonist anti __SP__ Apo 1 [__NODE__] protein antibody in cell culture increases ( in a dose dependent manner ) production of __SP__ __NODE__ protein .
COMP:V-N(In) (treat,Hela)
SUBJ:V-N (treat,cell)
COMP:V-N(with) (treat,cycloheximide)
COMP:V-N(with) (treat,__SP__)
OBJ:V-N (with,__NODE__)
MOD_ATT:N-ADJ (__SP__,zVAD)
MOD_ATT:N-N (__SP__,FMK)
MOD_ATT:N-N (__SP__,overproduce)
APPOS (protein,Apo)
MOD_ATT:N-N (__SP__,agonist)
MOD_ATT:N-N (__SP__,anti)
MOD_ATT:N-N (Apo,__SP__)
MOD_ATT:N-N (antibody,[__NODE__])
MOD_ATT:N-N (antibody,protein)
COMP:N-N(in) (antibody,increase)
MOD_ATT:N-N (increase,cell)
MOD_ATT:N-N (increase,culture)
MOD_ATT:N-N (manner,dose)
MOD_ATT:N-ADJ (manner,dependent)
COMP:N-N(of) (production,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)

Analyse 13

                  +-------------------COMP:V-N(with)------------------+                                                                                                                                                                                       
                  +------------COMP:V-N(with)------------+            |                          +-----------APPOS-----------+                           +------COMP:N-N(in)------+                                         +--------COMP:N-N(of)-------+     
      +COMP:V-N(In+                                  +--MOD_ATT:N-ADJ-+                          |         +-MOD_ATT:N-N+    |         +---MOD_ATT:N-N---+         +--MOD_ATT:N-N-+              +--MOD_ATT:N-N--+          |           +-MOD_ATT:N-ADJ-+     
      |    +SUBJ:V+-COMP:V-N(with)+                  +MOD+            |                  +MOD_ATT+         |      +MOD_A+MOD_+         |        +MOD_ATT:+         |     +MOD_ATT:+              |      +MOD_ATT:+          |           |       +MOD_ATT+     
      |    |      |               |                  |   |            |                  |       |         |      |     |    |         |        |        |         |     |        |              |      |        |          |           |       |       |     
 In Hela cells treated with cycloheximide and with zVAD FMK and overproducing __SP__ __NODE__ protein , agonist anti __SP__ Apo 1 [__NODE__] protein antibody in cell culture increases ( in a dose dependent manner ) production of __SP__ __NODE__ protein .
COMP:V-N(In) (treat,Hela)
SUBJ:V-N (treat,cell)
COMP:V-N(with) (treat,cycloheximide)
COMP:V-N(with) (treat,FMK)
COMP:V-N(with) (treat,overproduce)
MOD_ATT:N-ADJ (FMK,zVAD)
MOD_ATT:N-ADJ (overproduce,zVAD)
MOD_ATT:N-ADJ (protein,__NODE__)
APPOS (protein,Apo)
MOD_ATT:N-N (__SP__,agonist)
MOD_ATT:N-N (__SP__,anti)
MOD_ATT:N-N (Apo,__SP__)
MOD_ATT:N-N (antibody,[__NODE__])
MOD_ATT:N-N (antibody,protein)
COMP:N-N(in) (antibody,increase)
MOD_ATT:N-N (increase,cell)
MOD_ATT:N-N (increase,culture)
MOD_ATT:N-N (manner,dose)
MOD_ATT:N-N (manner,dependent)
COMP:N-N(of) (production,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)

Analyse 14

                  +------------------------COMP:V-N(with)------------------------+               +-----------APPOS-----------+                           +------COMP:N-N(in)------+                                         +--------COMP:N-N(of)-------+     
      +COMP:V-N(In+------------COMP:V-N(with)------------+                       |               |         +-MOD_ATT:N-N+    |         +---MOD_ATT:N-N---+         +--MOD_ATT:N-N-+              +--MOD_ATT:N-N--+          |           +-MOD_ATT:N-ADJ-+     
      |    +SUBJ:V+-COMP:V-N(with)+                  +MOD+            +MOD_ATT:N-+               |         |      +MOD_A+MOD_+         |        +MOD_ATT:+         |     +MOD_ATT:+              |      +MOD_ATT:+          |           |       +MOD_ATT+     
      |    |      |               |                  |   |            |          |               |         |      |     |    |         |        |        |         |     |        |              |      |        |          |           |       |       |     
 In Hela cells treated with cycloheximide and with zVAD FMK and overproducing __SP__ __NODE__ protein , agonist anti __SP__ Apo 1 [__NODE__] protein antibody in cell culture increases ( in a dose dependent manner ) production of __SP__ __NODE__ protein .
COMP:V-N(In) (treat,Hela)
SUBJ:V-N (treat,cell)
COMP:V-N(with) (treat,cycloheximide)
COMP:V-N(with) (treat,FMK)
COMP:V-N(with) (treat,__SP__)
MOD_ATT:N-ADJ (FMK,zVAD)
MOD_ATT:N-N (__SP__,overproduce)
APPOS (protein,Apo)
MOD_ATT:N-N (__SP__,agonist)
MOD_ATT:N-N (__SP__,anti)
MOD_ATT:N-N (Apo,__SP__)
MOD_ATT:N-N (antibody,[__NODE__])
MOD_ATT:N-N (antibody,protein)
COMP:N-N(in) (antibody,increase)
MOD_ATT:N-N (increase,cell)
MOD_ATT:N-N (increase,culture)
MOD_ATT:N-N (manner,dose)
MOD_ATT:N-ADJ (manner,dependent)
COMP:N-N(of) (production,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)

Analyse 15

                  +-------------------COMP:V-N(with)------------------+                                                                                                                                                                                       
                  +------------COMP:V-N(with)------------+            |                          +-----------APPOS-----------+                           +------COMP:N-N(in)------+                                         +--------COMP:N-N(of)-------+     
      +COMP:V-N(In+                                  +--MOD_ATT:N-ADJ-+          +-MOD_ATT:N-ADJ-+         +-MOD_ATT:N-N+    |         +---MOD_ATT:N-N---+         +--MOD_ATT:N-N-+              +--MOD_ATT:N-N--+          |           +-MOD_ATT:N-ADJ-+     
      |    +SUBJ:V+-COMP:V-N(with)+                  +MOD+            |          |       +MOD_ATT+         |      +MOD_A+MOD_+         |        +MOD_ATT:+         |     +MOD_ATT:+              |      +MOD_ATT:+          |           |       +MOD_ATT+     
      |    |      |               |                  |   |            |          |       |       |         |      |     |    |         |        |        |         |     |        |              |      |        |          |           |       |       |     
 In Hela cells treated with cycloheximide and with zVAD FMK and overproducing __SP__ __NODE__ protein , agonist anti __SP__ Apo 1 [__NODE__] protein antibody in cell culture increases ( in a dose dependent manner ) production of __SP__ __NODE__ protein .
COMP:V-N(In) (treat,Hela)
SUBJ:V-N (treat,cell)
COMP:V-N(with) (treat,cycloheximide)
COMP:V-N(with) (treat,FMK)
COMP:V-N(with) (treat,overproduce)
MOD_ATT:N-ADJ (FMK,zVAD)
MOD_ATT:N-ADJ (overproduce,zVAD)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)
APPOS (protein,Apo)
MOD_ATT:N-N (__SP__,agonist)
MOD_ATT:N-N (__SP__,anti)
MOD_ATT:N-N (Apo,__SP__)
MOD_ATT:N-N (antibody,[__NODE__])
MOD_ATT:N-N (antibody,protein)
COMP:N-N(in) (antibody,increase)
MOD_ATT:N-N (increase,cell)
MOD_ATT:N-N (increase,culture)
MOD_ATT:N-N (manner,dose)
MOD_ATT:N-ADJ (manner,dependent)
COMP:N-N(of) (production,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)

Analyse 16

                  +-------------------COMP:V-N(with)------------------+                                                                                                                                                                                       
                  +------------COMP:V-N(with)------------+            |                          +-----------APPOS-----------+                           +------COMP:N-N(in)------+                                         +--------COMP:N-N(of)-------+     
      +COMP:V-N(In+                             +-------------OBJ:V-N------------+               |         +-MOD_ATT:N-N+    |         +---MOD_ATT:N-N---+         +--MOD_ATT:N-N-+              +--MOD_ATT:N-N--+          |           +-MOD_ATT:N-ADJ-+     
      |    +SUBJ:V+-COMP:V-N(with)+             |    +MOD+            |          |       +MOD_ATT+         |      +MOD_A+MOD_+         |        +MOD_ATT:+         |     +MOD_ATT:+              |      +MOD_ATT:+          |           |       +MOD_ATT+     
      |    |      |               |             |    |   |            |          |       |       |         |      |     |    |         |        |        |         |     |        |              |      |        |          |           |       |       |     
 In Hela cells treated with cycloheximide and with zVAD FMK and overproducing __SP__ __NODE__ protein , agonist anti __SP__ Apo 1 [__NODE__] protein antibody in cell culture increases ( in a dose dependent manner ) production of __SP__ __NODE__ protein .
COMP:V-N(In) (treat,Hela)
SUBJ:V-N (treat,cell)
COMP:V-N(with) (treat,cycloheximide)
COMP:V-N(with) (treat,FMK)
COMP:V-N(with) (treat,overproduce)
OBJ:V-N (with,__SP__)
MOD_ATT:N-ADJ (FMK,zVAD)
MOD_ATT:N-ADJ (protein,__NODE__)
APPOS (protein,Apo)
MOD_ATT:N-N (__SP__,agonist)
MOD_ATT:N-N (__SP__,anti)
MOD_ATT:N-N (Apo,__SP__)
MOD_ATT:N-N (antibody,[__NODE__])
MOD_ATT:N-N (antibody,protein)
COMP:N-N(in) (antibody,increase)
MOD_ATT:N-N (increase,cell)
MOD_ATT:N-N (increase,culture)
MOD_ATT:N-N (manner,dose)
MOD_ATT:N-N (manner,dependent)
COMP:N-N(of) (production,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)

Analyse 17

                  +-------------------COMP:V-N(with)------------------+                                                                                                                                                                                       
                  |                             +-----------------OBJ:V-N----------------+                                                                                                                                                                    
                  +------------COMP:V-N(with)------------+            |                  |       +-----------APPOS-----------+                           +------COMP:N-N(in)------+                                         +--------COMP:N-N(of)-------+     
      +COMP:V-N(In+                             |    +--MOD_ATT:N-ADJ-+                  |       |         +-MOD_ATT:N-N+    |         +---MOD_ATT:N-N---+         +--MOD_ATT:N-N-+              +--MOD_ATT:N-N--+          |           +-MOD_ATT:N-ADJ-+     
      |    +SUBJ:V+-COMP:V-N(with)+             |    +MOD+            |          +MOD_ATT+       |         |      +MOD_A+MOD_+         |        +MOD_ATT:+         |     +MOD_ATT:+              |      +MOD_ATT:+          |           |       +MOD_ATT+     
      |    |      |               |             |    |   |            |          |       |       |         |      |     |    |         |        |        |         |     |        |              |      |        |          |           |       |       |     
 In Hela cells treated with cycloheximide and with zVAD FMK and overproducing __SP__ __NODE__ protein , agonist anti __SP__ Apo 1 [__NODE__] protein antibody in cell culture increases ( in a dose dependent manner ) production of __SP__ __NODE__ protein .
COMP:V-N(In) (treat,Hela)
SUBJ:V-N (treat,cell)
COMP:V-N(with) (treat,cycloheximide)
COMP:V-N(with) (treat,FMK)
COMP:V-N(with) (treat,overproduce)
OBJ:V-N (with,__NODE__)
MOD_ATT:N-ADJ (FMK,zVAD)
MOD_ATT:N-ADJ (overproduce,zVAD)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (protein,Apo)
MOD_ATT:N-N (__SP__,agonist)
MOD_ATT:N-N (__SP__,anti)
MOD_ATT:N-N (Apo,__SP__)
MOD_ATT:N-N (antibody,[__NODE__])
MOD_ATT:N-N (antibody,protein)
COMP:N-N(in) (antibody,increase)
MOD_ATT:N-N (increase,cell)
MOD_ATT:N-N (increase,culture)
MOD_ATT:N-N (manner,dose)
MOD_ATT:N-N (manner,dependent)
COMP:N-N(of) (production,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)

Analyse 18

                  +------------------------COMP:V-N(with)------------------------+                                                                                                                                                                            
                  |                             +-----------------OBJ:V-N----------------+       +-----------APPOS-----------+                           +------COMP:N-N(in)------+                                         +--------COMP:N-N(of)-------+     
      +COMP:V-N(In+------------COMP:V-N(with)------------+                       |       |       |         +-MOD_ATT:N-N+    |         +---MOD_ATT:N-N---+         +--MOD_ATT:N-N-+              +--MOD_ATT:N-N--+          |           +-MOD_ATT:N-ADJ-+     
      |    +SUBJ:V+-COMP:V-N(with)+             |    +MOD+            +MOD_ATT:N-+       |       |         |      +MOD_A+MOD_+         |        +MOD_ATT:+         |     +MOD_ATT:+              |      +MOD_ATT:+          |           |       +MOD_ATT+     
      |    |      |               |             |    |   |            |          |       |       |         |      |     |    |         |        |        |         |     |        |              |      |        |          |           |       |       |     
 In Hela cells treated with cycloheximide and with zVAD FMK and overproducing __SP__ __NODE__ protein , agonist anti __SP__ Apo 1 [__NODE__] protein antibody in cell culture increases ( in a dose dependent manner ) production of __SP__ __NODE__ protein .
COMP:V-N(In) (treat,Hela)
SUBJ:V-N (treat,cell)
COMP:V-N(with) (treat,cycloheximide)
COMP:V-N(with) (treat,FMK)
COMP:V-N(with) (treat,__SP__)
OBJ:V-N (with,__NODE__)
MOD_ATT:N-ADJ (FMK,zVAD)
MOD_ATT:N-N (__SP__,overproduce)
APPOS (protein,Apo)
MOD_ATT:N-N (__SP__,agonist)
MOD_ATT:N-N (__SP__,anti)
MOD_ATT:N-N (Apo,__SP__)
MOD_ATT:N-N (antibody,[__NODE__])
MOD_ATT:N-N (antibody,protein)
COMP:N-N(in) (antibody,increase)
MOD_ATT:N-N (increase,cell)
MOD_ATT:N-N (increase,culture)
MOD_ATT:N-N (manner,dose)
MOD_ATT:N-ADJ (manner,dependent)
COMP:N-N(of) (production,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)

Analyse 19

                  +------------------------COMP:V-N(with)------------------------+                                                                                                                                                                            
                  |                             +-----------------OBJ:V-N----------------+       +-----------APPOS-----------+                           +------COMP:N-N(in)------+                                         +--------COMP:N-N(of)-------+     
      +COMP:V-N(In+------------COMP:V-N(with)------------+                       |       |       |         +-MOD_ATT:N-N+    |         +---MOD_ATT:N-N---+         +--MOD_ATT:N-N-+              +--MOD_ATT:N-N--+          |           +-MOD_ATT:N-ADJ-+     
      |    +SUBJ:V+-COMP:V-N(with)+             |    +MOD+            +MOD_ATT:N-+       |       |         |      +MOD_A+MOD_+         |        +MOD_ATT:+         |     +MOD_ATT:+              |      +MOD_ATT:+          |           |       +MOD_ATT+     
      |    |      |               |             |    |   |            |          |       |       |         |      |     |    |         |        |        |         |     |        |              |      |        |          |           |       |       |     
 In Hela cells treated with cycloheximide and with zVAD FMK and overproducing __SP__ __NODE__ protein , agonist anti __SP__ Apo 1 [__NODE__] protein antibody in cell culture increases ( in a dose dependent manner ) production of __SP__ __NODE__ protein .
COMP:V-N(In) (treat,Hela)
SUBJ:V-N (treat,cell)
COMP:V-N(with) (treat,cycloheximide)
COMP:V-N(with) (treat,FMK)
COMP:V-N(with) (treat,__SP__)
OBJ:V-N (with,__NODE__)
MOD_ATT:N-ADJ (FMK,zVAD)
MOD_ATT:N-N (__SP__,overproduce)
APPOS (protein,Apo)
MOD_ATT:N-N (__SP__,agonist)
MOD_ATT:N-N (__SP__,anti)
MOD_ATT:N-N (Apo,__SP__)
MOD_ATT:N-N (antibody,[__NODE__])
MOD_ATT:N-N (antibody,protein)
COMP:N-N(in) (antibody,increase)
MOD_ATT:N-N (increase,cell)
MOD_ATT:N-N (increase,culture)
MOD_ATT:N-N (manner,dose)
MOD_ATT:N-ADJ (manner,dependent)
COMP:N-N(of) (production,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)

Analyse 20

                  +-------------------COMP:V-N(with)------------------+                                                                                                                                                                                       
                  +------------COMP:V-N(with)------------+            |                          +-----------APPOS-----------+                           +------COMP:N-N(in)------+                                         +--------COMP:N-N(of)-------+     
      +COMP:V-N(In+                                  +--MOD_ATT:N-ADJ-+                          |         +-MOD_ATT:N-N+    |         +---MOD_ATT:N-N---+         +--MOD_ATT:N-N-+              +--MOD_ATT:N-N--+          |           +-MOD_ATT:N-ADJ-+     
      |    +SUBJ:V+-COMP:V-N(with)+                  +MOD+            |                  +MOD_ATT+         |      +MOD_A+MOD_+         |        +MOD_ATT:+         |     +MOD_ATT:+              |      +MOD_ATT:+          |           |       +MOD_ATT+     
      |    |      |               |                  |   |            |                  |       |         |      |     |    |         |        |        |         |     |        |              |      |        |          |           |       |       |     
 In Hela cells treated with cycloheximide and with zVAD FMK and overproducing __SP__ __NODE__ protein , agonist anti __SP__ Apo 1 [__NODE__] protein antibody in cell culture increases ( in a dose dependent manner ) production of __SP__ __NODE__ protein .
COMP:V-N(In) (treat,Hela)
SUBJ:V-N (treat,cell)
COMP:V-N(with) (treat,cycloheximide)
COMP:V-N(with) (treat,FMK)
COMP:V-N(with) (treat,overproduce)
MOD_ATT:N-ADJ (FMK,zVAD)
MOD_ATT:N-ADJ (overproduce,zVAD)
MOD_ATT:N-ADJ (protein,__NODE__)
APPOS (protein,Apo)
MOD_ATT:N-N (__SP__,agonist)
MOD_ATT:N-N (__SP__,anti)
MOD_ATT:N-N (Apo,__SP__)
MOD_ATT:N-N (antibody,[__NODE__])
MOD_ATT:N-N (antibody,protein)
COMP:N-N(in) (antibody,increase)
MOD_ATT:N-N (increase,cell)
MOD_ATT:N-N (increase,culture)
MOD_ATT:N-N (manner,dose)
MOD_ATT:N-ADJ (manner,dependent)
COMP:N-N(of) (production,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)

Analyse 21

                  +-------------------COMP:V-N(with)------------------+                          +-----------APPOS-----------+                           +------COMP:N-N(in)------+                                         +--------COMP:N-N(of)-------+     
      +COMP:V-N(In+------------COMP:V-N(with)------------+            |                          |         +-MOD_ATT:N-N+    |         +---MOD_ATT:N-N---+         +--MOD_ATT:N-N-+              +--MOD_ATT:N-N--+          |           +-MOD_ATT:N-ADJ-+     
      |    +SUBJ:V+-COMP:V-N(with)+                  +MOD+            |                  +MOD_ATT+         |      +MOD_A+MOD_+         |        +MOD_ATT:+         |     +MOD_ATT:+              |      +MOD_ATT:+          |           |       +MOD_ATT+     
      |    |      |               |                  |   |            |                  |       |         |      |     |    |         |        |        |         |     |        |              |      |        |          |           |       |       |     
 In Hela cells treated with cycloheximide and with zVAD FMK and overproducing __SP__ __NODE__ protein , agonist anti __SP__ Apo 1 [__NODE__] protein antibody in cell culture increases ( in a dose dependent manner ) production of __SP__ __NODE__ protein .
COMP:V-N(In) (treat,Hela)
SUBJ:V-N (treat,cell)
COMP:V-N(with) (treat,cycloheximide)
COMP:V-N(with) (treat,FMK)
COMP:V-N(with) (treat,overproduce)
MOD_ATT:N-ADJ (FMK,zVAD)
MOD_ATT:N-ADJ (protein,__NODE__)
APPOS (protein,Apo)
MOD_ATT:N-N (__SP__,agonist)
MOD_ATT:N-N (__SP__,anti)
MOD_ATT:N-N (Apo,__SP__)
MOD_ATT:N-N (antibody,[__NODE__])
MOD_ATT:N-N (antibody,protein)
COMP:N-N(in) (antibody,increase)
MOD_ATT:N-N (increase,cell)
MOD_ATT:N-N (increase,culture)
MOD_ATT:N-N (manner,dose)
MOD_ATT:N-ADJ (manner,dependent)
COMP:N-N(of) (production,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)

Analyse 22

                  +-------------------COMP:V-N(with)------------------+                                                                                                                                                                                       
                  +------------COMP:V-N(with)------------+            |                          +-----------APPOS-----------+                           +------COMP:N-N(in)------+                                         +--------COMP:N-N(of)-------+     
      +COMP:V-N(In+                             +-------------OBJ:V-N------------+               |         +-MOD_ATT:N-N+    |         +---MOD_ATT:N-N---+         +--MOD_ATT:N-N-+              +--MOD_ATT:N-N--+          |           +-MOD_ATT:N-ADJ-+     
      |    +SUBJ:V+-COMP:V-N(with)+             |    +MOD+            |          |       +MOD_ATT+         |      +MOD_A+MOD_+         |        +MOD_ATT:+         |     +MOD_ATT:+              |      +MOD_ATT:+          |           |       +MOD_ATT+     
      |    |      |               |             |    |   |            |          |       |       |         |      |     |    |         |        |        |         |     |        |              |      |        |          |           |       |       |     
 In Hela cells treated with cycloheximide and with zVAD FMK and overproducing __SP__ __NODE__ protein , agonist anti __SP__ Apo 1 [__NODE__] protein antibody in cell culture increases ( in a dose dependent manner ) production of __SP__ __NODE__ protein .
COMP:V-N(In) (treat,Hela)
SUBJ:V-N (treat,cell)
COMP:V-N(with) (treat,cycloheximide)
COMP:V-N(with) (treat,FMK)
COMP:V-N(with) (treat,overproduce)
OBJ:V-N (with,__SP__)
MOD_ATT:N-ADJ (FMK,zVAD)
MOD_ATT:N-ADJ (protein,__NODE__)
APPOS (protein,Apo)
MOD_ATT:N-N (__SP__,agonist)
MOD_ATT:N-N (__SP__,anti)
MOD_ATT:N-N (Apo,__SP__)
MOD_ATT:N-N (antibody,[__NODE__])
MOD_ATT:N-N (antibody,protein)
COMP:N-N(in) (antibody,increase)
MOD_ATT:N-N (increase,cell)
MOD_ATT:N-N (increase,culture)
MOD_ATT:N-N (manner,dose)
MOD_ATT:N-ADJ (manner,dependent)
COMP:N-N(of) (production,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)

Analyse 23

                  +-------------------COMP:V-N(with)------------------+                                                                                                                                                                                       
                  |                             +-----------------OBJ:V-N----------------+                                                                                                                                                                    
                  +------------COMP:V-N(with)------------+            |                  |       +-----------APPOS-----------+                           +------COMP:N-N(in)------+                                         +--------COMP:N-N(of)-------+     
      +COMP:V-N(In+                             |    +--MOD_ATT:N-ADJ-+                  |       |         +-MOD_ATT:N-N+    |         +---MOD_ATT:N-N---+         +--MOD_ATT:N-N-+              +--MOD_ATT:N-N--+          |           +-MOD_ATT:N-ADJ-+     
      |    +SUBJ:V+-COMP:V-N(with)+             |    +MOD+            |          +MOD_ATT+       |         |      +MOD_A+MOD_+         |        +MOD_ATT:+         |     +MOD_ATT:+              |      +MOD_ATT:+          |           |       +MOD_ATT+     
      |    |      |               |             |    |   |            |          |       |       |         |      |     |    |         |        |        |         |     |        |              |      |        |          |           |       |       |     
 In Hela cells treated with cycloheximide and with zVAD FMK and overproducing __SP__ __NODE__ protein , agonist anti __SP__ Apo 1 [__NODE__] protein antibody in cell culture increases ( in a dose dependent manner ) production of __SP__ __NODE__ protein .
COMP:V-N(In) (treat,Hela)
SUBJ:V-N (treat,cell)
COMP:V-N(with) (treat,cycloheximide)
COMP:V-N(with) (treat,FMK)
COMP:V-N(with) (treat,overproduce)
OBJ:V-N (with,__NODE__)
MOD_ATT:N-ADJ (FMK,zVAD)
MOD_ATT:N-ADJ (overproduce,zVAD)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (protein,Apo)
MOD_ATT:N-N (__SP__,agonist)
MOD_ATT:N-N (__SP__,anti)
MOD_ATT:N-N (Apo,__SP__)
MOD_ATT:N-N (antibody,[__NODE__])
MOD_ATT:N-N (antibody,protein)
COMP:N-N(in) (antibody,increase)
MOD_ATT:N-N (increase,cell)
MOD_ATT:N-N (increase,culture)
MOD_ATT:N-N (manner,dose)
MOD_ATT:N-ADJ (manner,dependent)
COMP:N-N(of) (production,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)

Analyse 24

                         +------------------------OBJ:V-N------------------------+                                                                                                                                                                            
                  +-------------------COMP:V-N(with)------------------+          |                                                                                                                                                                            
                  +------------COMP:V-N(with)------------+            |          |                                                                                                                                                                            
                  |      |                      +-------------OBJ:V-N------------+               +-----------APPOS-----------+                           +------COMP:N-N(in)------+                                         +--------COMP:N-N(of)-------+     
      +COMP:V-N(In+      |                      |    +--MOD_ATT:N-ADJ-+          |               |         +-MOD_ATT:N-N+    |         +---MOD_ATT:N-N---+         +--MOD_ATT:N-N-+              +--MOD_ATT:N-N--+          |           +-MOD_ATT:N-ADJ-+     
      |    +SUBJ:V+-COMP:V-N(with)+             |    +MOD+            |          |       +MOD_ATT+         |      +MOD_A+MOD_+         |        +MOD_ATT:+         |     +MOD_ATT:+              |      +MOD_ATT:+          |           |       +MOD_ATT+     
      |    |      |      |        |             |    |   |            |          |       |       |         |      |     |    |         |        |        |         |     |        |              |      |        |          |           |       |       |     
 In Hela cells treated with cycloheximide and with zVAD FMK and overproducing __SP__ __NODE__ protein , agonist anti __SP__ Apo 1 [__NODE__] protein antibody in cell culture increases ( in a dose dependent manner ) production of __SP__ __NODE__ protein .
COMP:V-N(In) (treat,Hela)
SUBJ:V-N (treat,cell)
COMP:V-N(with) (treat,cycloheximide)
COMP:V-N(with) (treat,FMK)
COMP:V-N(with) (treat,overproduce)
OBJ:V-N (with,__SP__)
OBJ:V-N (with,__SP__)
MOD_ATT:N-ADJ (FMK,zVAD)
MOD_ATT:N-ADJ (overproduce,zVAD)
MOD_ATT:N-ADJ (protein,__NODE__)
APPOS (protein,Apo)
MOD_ATT:N-N (__SP__,agonist)
MOD_ATT:N-N (__SP__,anti)
MOD_ATT:N-N (Apo,__SP__)
MOD_ATT:N-N (antibody,[__NODE__])
MOD_ATT:N-N (antibody,protein)
COMP:N-N(in) (antibody,increase)
MOD_ATT:N-N (increase,cell)
MOD_ATT:N-N (increase,culture)
MOD_ATT:N-N (manner,dose)
MOD_ATT:N-ADJ (manner,dependent)
COMP:N-N(of) (production,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)

Analyse 25

                         +------------------------OBJ:V-N------------------------+                                                                                                                                                                            
                  +-------------------COMP:V-N(with)------------------+          |                                                                                                                                                                            
                  +------------COMP:V-N(with)------------+            |          |                                                                                                                                                                            
                  |      |                      +-------------OBJ:V-N------------+               +-----------APPOS-----------+                           +------COMP:N-N(in)------+                                         +--------COMP:N-N(of)-------+     
      +COMP:V-N(In+      |                      |    +--MOD_ATT:N-ADJ-+          |               |         +-MOD_ATT:N-N+    |         +---MOD_ATT:N-N---+         +--MOD_ATT:N-N-+              +--MOD_ATT:N-N--+          |           +-MOD_ATT:N-ADJ-+     
      |    +SUBJ:V+-COMP:V-N(with)+             |    +MOD+            |          |       +MOD_ATT+         |      +MOD_A+MOD_+         |        +MOD_ATT:+         |     +MOD_ATT:+              |      +MOD_ATT:+          |           |       +MOD_ATT+     
      |    |      |      |        |             |    |   |            |          |       |       |         |      |     |    |         |        |        |         |     |        |              |      |        |          |           |       |       |     
 In Hela cells treated with cycloheximide and with zVAD FMK and overproducing __SP__ __NODE__ protein , agonist anti __SP__ Apo 1 [__NODE__] protein antibody in cell culture increases ( in a dose dependent manner ) production of __SP__ __NODE__ protein .
COMP:V-N(In) (treat,Hela)
SUBJ:V-N (treat,cell)
COMP:V-N(with) (treat,cycloheximide)
COMP:V-N(with) (treat,FMK)
COMP:V-N(with) (treat,overproduce)
OBJ:V-N (with,__SP__)
OBJ:V-N (with,__SP__)
MOD_ATT:N-ADJ (FMK,zVAD)
MOD_ATT:N-ADJ (overproduce,zVAD)
MOD_ATT:N-ADJ (protein,__NODE__)
APPOS (protein,Apo)
MOD_ATT:N-N (__SP__,agonist)
MOD_ATT:N-N (__SP__,anti)
MOD_ATT:N-N (Apo,__SP__)
MOD_ATT:N-N (antibody,[__NODE__])
MOD_ATT:N-N (antibody,protein)
COMP:N-N(in) (antibody,increase)
MOD_ATT:N-N (increase,cell)
MOD_ATT:N-N (increase,culture)
MOD_ATT:N-N (manner,dose)
MOD_ATT:N-ADJ (manner,dependent)
COMP:N-N(of) (production,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)

Analyse 26

                  +------------------------COMP:V-N(with)------------------------+                                                                                                                                                                            
                  |                             +-----------------OBJ:V-N----------------+---------------APPOS---------------+                           +--------SUBJ:V-N--------+---------COMP:V-N(in)---------+          +--------COMP:N-N(of)-------+     
      +COMP:V-N(In+------------COMP:V-N(with)------------+                       |       |                 +-MOD_ATT:N-N+    |         +---MOD_ATT:N-N---+--COMP:N-N(in)-+        |              +--MOD_ATT:N-N--+          |           +-MOD_ATT:N-ADJ-+     
      |    +SUBJ:V+-COMP:V-N(with)+             |    +MOD+            +MOD_ATT:N-+       |                 |      +MOD_A+MOD_+         |        +MOD_ATT:+         +MOD_A+        |              |      +MOD_ATT:+          |           |       +MOD_ATT+     
      |    |      |               |             |    |   |            |          |       |                 |      |     |    |         |        |        |         |     |        |              |      |        |          |           |       |       |     
 In Hela cells treated with cycloheximide and with zVAD FMK and overproducing __SP__ __NODE__ protein , agonist anti __SP__ Apo 1 [__NODE__] protein antibody in cell culture increases ( in a dose dependent manner ) production of __SP__ __NODE__ protein .
COMP:V-N(In) (treat,Hela)
SUBJ:V-N (treat,cell)
COMP:V-N(with) (treat,cycloheximide)
COMP:V-N(with) (treat,FMK)
COMP:V-N(with) (treat,__SP__)
OBJ:V-N (with,__NODE__)
MOD_ATT:N-ADJ (FMK,zVAD)
MOD_ATT:N-ADJ (__SP__,overproduce)
APPOS (__NODE__,Apo)
MOD_ATT:N-N (__SP__,agonist)
MOD_ATT:N-N (__SP__,anti)
MOD_ATT:N-N (Apo,__SP__)
MOD_ATT:N-N (antibody,[__NODE__])
MOD_ATT:N-N (antibody,protein)
COMP:N-N(in) (antibody,culture)
MOD_ATT:N-N (culture,cell)
SUBJ:V-N (increase,antibody)
COMP:V-N(in) (increase,manner)
MOD_ATT:N-N (manner,dose)
MOD_ATT:N-N (manner,dependent)
COMP:N-N(of) (production,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)

Analyse 27

                                                                                                 +-----------APPOS-----------+                           +--------SUBJ:V-N--------+---------COMP:V-N(in)---------+          +--------COMP:N-N(of)-------+     
      +COMP:V-N(In+                                      +------------SUBJ:V-N-----------+       |         +-MOD_ATT:N-N+    |         +---MOD_ATT:N-N---+--COMP:N-N(in)-+        |              +--MOD_ATT:N-N--+          |           +-MOD_ATT:N-ADJ-+     
      |    +SUBJ:V+-COMP:V-N(with)+                  +MOD+            +MOD_ATT:N-+SUBJ:V-+OBJ:V-N+         |      +MOD_A+MOD_+         |        +MOD_ATT:+         +MOD_A+        |              |      +MOD_ATT:+          |           |       +MOD_ATT+     
      |    |      |               |                  |   |            |          |       |       |         |      |     |    |         |        |        |         |     |        |              |      |        |          |           |       |       |     
 In Hela cells treated with cycloheximide and with zVAD FMK and overproducing __SP__ __NODE__ protein , agonist anti __SP__ Apo 1 [__NODE__] protein antibody in cell culture increases ( in a dose dependent manner ) production of __SP__ __NODE__ protein .
COMP:V-N(In) (treat,Hela)
SUBJ:V-N (treat,cell)
COMP:V-N(with) (treat,cycloheximide)
MOD_ATT:N-ADJ (FMK,zVAD)
MOD_ATT:N-N (__SP__,overproduce)
SUBJ:V-N (__NODE__,FMK)
SUBJ:V-N (__NODE__,__SP__)
OBJ:V-N (__NODE__,protein)
APPOS (protein,Apo)
MOD_ATT:N-N (__SP__,agonist)
MOD_ATT:N-N (__SP__,anti)
MOD_ATT:N-N (Apo,__SP__)
MOD_ATT:N-N (antibody,[__NODE__])
MOD_ATT:N-N (antibody,protein)
COMP:N-N(in) (antibody,culture)
MOD_ATT:N-N (culture,cell)
SUBJ:V-N (increase,antibody)
COMP:V-N(in) (increase,manner)
MOD_ATT:N-N (manner,dose)
MOD_ATT:N-N (manner,dependent)
COMP:N-N(of) (production,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)

Analyse 28

                                                         +------------SUBJ:V-N-----------+       +-----------APPOS-----------+                           +--------SUBJ:V-N--------+---------COMP:V-N(in)---------+          +--------COMP:N-N(of)-------+     
      +COMP:V-N(In+                                  +-------MOD_ATT:N-ADJ-------+       |       |         +-MOD_ATT:N-N+    |         +---MOD_ATT:N-N---+--COMP:N-N(in)-+        |              +--MOD_ATT:N-N--+          |           +-MOD_ATT:N-ADJ-+     
      |    +SUBJ:V+-COMP:V-N(with)+                  +MOD+            +MOD_ATT:N-+SUBJ:V-+OBJ:V-N+         |      +MOD_A+MOD_+         |        +MOD_ATT:+         +MOD_A+        |              |      +MOD_ATT:+          |           |       +MOD_ATT+     
      |    |      |               |                  |   |            |          |       |       |         |      |     |    |         |        |        |         |     |        |              |      |        |          |           |       |       |     
 In Hela cells treated with cycloheximide and with zVAD FMK and overproducing __SP__ __NODE__ protein , agonist anti __SP__ Apo 1 [__NODE__] protein antibody in cell culture increases ( in a dose dependent manner ) production of __SP__ __NODE__ protein .
COMP:V-N(In) (treat,Hela)
SUBJ:V-N (treat,cell)
COMP:V-N(with) (treat,cycloheximide)
MOD_ATT:N-ADJ (FMK,zVAD)
MOD_ATT:N-ADJ (__SP__,zVAD)
MOD_ATT:N-N (__SP__,overproduce)
SUBJ:V-N (__NODE__,FMK)
SUBJ:V-N (__NODE__,__SP__)
OBJ:V-N (__NODE__,protein)
APPOS (protein,Apo)
MOD_ATT:N-N (__SP__,agonist)
MOD_ATT:N-N (__SP__,anti)
MOD_ATT:N-N (Apo,__SP__)
MOD_ATT:N-N (antibody,[__NODE__])
MOD_ATT:N-N (antibody,protein)
COMP:N-N(in) (antibody,culture)
MOD_ATT:N-N (culture,cell)
SUBJ:V-N (increase,antibody)
COMP:V-N(in) (increase,manner)
MOD_ATT:N-N (manner,dose)
MOD_ATT:N-ADJ (manner,dependent)
COMP:N-N(of) (production,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)

Analyse 29

                                                         +------------SUBJ:V-N-----------+       +-----------APPOS-----------+                           +------COMP:N-N(in)------+                                         +--------COMP:N-N(of)-------+     
      +COMP:V-N(In+                                      |            +-----SUBJ:V-N-----+       |         +-MOD_ATT:N-N+    |         +---MOD_ATT:N-N---+         +--MOD_ATT:N-N-+              +--MOD_ATT:N-N--+          |           +-MOD_ATT:N-ADJ-+     
      |    +SUBJ:V+-COMP:V-N(with)+                  +MOD+            +--OBJ:V-N-+       +OBJ:V-N+         |      +MOD_A+MOD_+         |        +MOD_ATT:+         |     +MOD_ATT:+              |      +MOD_ATT:+          |           |       +MOD_ATT+     
      |    |      |               |                  |   |            |          |       |       |         |      |     |    |         |        |        |         |     |        |              |      |        |          |           |       |       |     
 In Hela cells treated with cycloheximide and with zVAD FMK and overproducing __SP__ __NODE__ protein , agonist anti __SP__ Apo 1 [__NODE__] protein antibody in cell culture increases ( in a dose dependent manner ) production of __SP__ __NODE__ protein .
COMP:V-N(In) (treat,Hela)
SUBJ:V-N (treat,cell)
COMP:V-N(with) (treat,cycloheximide)
MOD_ATT:N-ADJ (FMK,zVAD)
OBJ:V-N (overproduce,__SP__)
SUBJ:V-N (__NODE__,FMK)
SUBJ:V-N (__NODE__,overproduce)
OBJ:V-N (__NODE__,protein)
APPOS (protein,Apo)
MOD_ATT:N-N (__SP__,agonist)
MOD_ATT:N-N (__SP__,anti)
MOD_ATT:N-N (Apo,__SP__)
MOD_ATT:N-N (antibody,[__NODE__])
MOD_ATT:N-N (antibody,protein)
COMP:N-N(in) (antibody,increase)
MOD_ATT:N-N (increase,cell)
MOD_ATT:N-N (increase,culture)
MOD_ATT:N-N (manner,dose)
MOD_ATT:N-ADJ (manner,dependent)
COMP:N-N(of) (production,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)

Analyse 30

                                                                                                 +-----------APPOS-----------+                           +------COMP:N-N(in)------+                                         +--------COMP:N-N(of)-------+     
      +COMP:V-N(In+                                      +--------SUBJ:V-N-------+----OBJ:V-N----+         +-MOD_ATT:N-N+    |         +---MOD_ATT:N-N---+         +--MOD_ATT:N-N-+              +--MOD_ATT:N-N--+          |           +-MOD_ATT:N-ADJ-+     
      |    +SUBJ:V+-COMP:V-N(with)+                  +MOD+            +-SUBJ:V-N-+       +MOD_ATT+         |      +MOD_A+MOD_+         |        +MOD_ATT:+         |     +MOD_ATT:+              |      +MOD_ATT:+          |           |       +MOD_ATT+     
      |    |      |               |                  |   |            |          |       |       |         |      |     |    |         |        |        |         |     |        |              |      |        |          |           |       |       |     
 In Hela cells treated with cycloheximide and with zVAD FMK and overproducing __SP__ __NODE__ protein , agonist anti __SP__ Apo 1 [__NODE__] protein antibody in cell culture increases ( in a dose dependent manner ) production of __SP__ __NODE__ protein .
COMP:V-N(In) (treat,Hela)
SUBJ:V-N (treat,cell)
COMP:V-N(with) (treat,cycloheximide)
MOD_ATT:N-ADJ (FMK,zVAD)
SUBJ:V-N (__SP__,FMK)
SUBJ:V-N (__SP__,overproduce)
OBJ:V-N (__SP__,protein)
MOD_ATT:N-ADJ (protein,__NODE__)
APPOS (protein,Apo)
MOD_ATT:N-N (__SP__,agonist)
MOD_ATT:N-N (__SP__,anti)
MOD_ATT:N-N (Apo,__SP__)
MOD_ATT:N-N (antibody,[__NODE__])
MOD_ATT:N-N (antibody,protein)
COMP:N-N(in) (antibody,increase)
MOD_ATT:N-N (increase,cell)
MOD_ATT:N-N (increase,culture)
MOD_ATT:N-N (manner,dose)
MOD_ATT:N-ADJ (manner,dependent)
COMP:N-N(of) (production,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)

Analyse 31

                  +------------------------COMP:V-N(with)------------------------+                                                                                                                                                                            
                  |                             +-----------------OBJ:V-N----------------+---------------APPOS---------------+                           +--------SUBJ:V-N--------+---------COMP:V-N(in)---------+          +--------COMP:N-N(of)-------+     
      +COMP:V-N(In+------------COMP:V-N(with)------------+                       |       |                 +-MOD_ATT:N-N+    |         +---MOD_ATT:N-N---+--COMP:N-N(in)-+        |              +--MOD_ATT:N-N--+          |           +-MOD_ATT:N-ADJ-+     
      |    +SUBJ:V+-COMP:V-N(with)+             |    +MOD+            +MOD_ATT:N-+       |                 |      +MOD_A+MOD_+         |        +MOD_ATT:+         +MOD_A+        |              |      +MOD_ATT:+          |           |       +MOD_ATT+     
      |    |      |               |             |    |   |            |          |       |                 |      |     |    |         |        |        |         |     |        |              |      |        |          |           |       |       |     
 In Hela cells treated with cycloheximide and with zVAD FMK and overproducing __SP__ __NODE__ protein , agonist anti __SP__ Apo 1 [__NODE__] protein antibody in cell culture increases ( in a dose dependent manner ) production of __SP__ __NODE__ protein .
COMP:V-N(In) (treat,Hela)
SUBJ:V-N (treat,cell)
COMP:V-N(with) (treat,cycloheximide)
COMP:V-N(with) (treat,FMK)
COMP:V-N(with) (treat,__SP__)
OBJ:V-N (with,__NODE__)
MOD_ATT:N-ADJ (FMK,zVAD)
MOD_ATT:N-N (__SP__,overproduce)
APPOS (__NODE__,Apo)
MOD_ATT:N-N (__SP__,agonist)
MOD_ATT:N-N (__SP__,anti)
MOD_ATT:N-N (Apo,__SP__)
MOD_ATT:N-N (antibody,[__NODE__])
MOD_ATT:N-N (antibody,protein)
COMP:N-N(in) (antibody,culture)
MOD_ATT:N-N (culture,cell)
SUBJ:V-N (increase,antibody)
COMP:V-N(in) (increase,manner)
MOD_ATT:N-N (manner,dose)
MOD_ATT:N-ADJ (manner,dependent)
COMP:N-N(of) (production,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)

Analyse 32

                                                                                                 +-----------APPOS-----------+                           +------COMP:N-N(in)------+                                         +--------COMP:N-N(of)-------+     
      +COMP:V-N(In+                                      +--------SUBJ:V-N-------+----OBJ:V-N----+         +-MOD_ATT:N-N+    |         +---MOD_ATT:N-N---+         +--MOD_ATT:N-N-+              +--MOD_ATT:N-N--+          |           +-MOD_ATT:N-ADJ-+     
      |    +SUBJ:V+-COMP:V-N(with)+                  +MOD+            +-SUBJ:V-N-+       +MOD_ATT+         |      +MOD_A+MOD_+         |        +MOD_ATT:+         |     +MOD_ATT:+              |      +MOD_ATT:+          |           |       +MOD_ATT+     
      |    |      |               |                  |   |            |          |       |       |         |      |     |    |         |        |        |         |     |        |              |      |        |          |           |       |       |     
 In Hela cells treated with cycloheximide and with zVAD FMK and overproducing __SP__ __NODE__ protein , agonist anti __SP__ Apo 1 [__NODE__] protein antibody in cell culture increases ( in a dose dependent manner ) production of __SP__ __NODE__ protein .
COMP:V-N(In) (treat,Hela)
SUBJ:V-N (treat,cell)
COMP:V-N(with) (treat,cycloheximide)
MOD_ATT:N-ADJ (FMK,zVAD)
SUBJ:V-N (__SP__,FMK)
SUBJ:V-N (__SP__,overproduce)
OBJ:V-N (__SP__,protein)
MOD_ATT:N-ADJ (protein,__NODE__)
APPOS (protein,Apo)
MOD_ATT:N-N (__SP__,agonist)
MOD_ATT:N-N (__SP__,anti)
MOD_ATT:N-N (Apo,__SP__)
MOD_ATT:N-N (antibody,[__NODE__])
MOD_ATT:N-N (antibody,protein)
COMP:N-N(in) (antibody,increase)
MOD_ATT:N-N (increase,cell)
MOD_ATT:N-N (increase,culture)
MOD_ATT:N-N (manner,dose)
MOD_ATT:N-N (manner,dependent)
COMP:N-N(of) (production,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)

Analyse 33

                  +-------------------COMP:V-N(with)------------------+                                                                                                                                                                                       
                  |                             +-----------------OBJ:V-N----------------+                                                                                                                                                                    
                  +------------COMP:V-N(with)------------+            |                  +---------------APPOS---------------+                           +--------SUBJ:V-N--------+---------COMP:V-N(in)---------+          +--------COMP:N-N(of)-------+     
      +COMP:V-N(In+                             |    +--MOD_ATT:N-ADJ-+                  |                 +-MOD_ATT:N-N+    |         +---MOD_ATT:N-N---+--COMP:N-N(in)-+        |              +--MOD_ATT:N-N--+          |           +-MOD_ATT:N-ADJ-+     
      |    +SUBJ:V+-COMP:V-N(with)+             |    +MOD+            |          +MOD_ATT+                 |      +MOD_A+MOD_+         |        +MOD_ATT:+         +MOD_A+        |              |      +MOD_ATT:+          |           |       +MOD_ATT+     
      |    |      |               |             |    |   |            |          |       |                 |      |     |    |         |        |        |         |     |        |              |      |        |          |           |       |       |     
 In Hela cells treated with cycloheximide and with zVAD FMK and overproducing __SP__ __NODE__ protein , agonist anti __SP__ Apo 1 [__NODE__] protein antibody in cell culture increases ( in a dose dependent manner ) production of __SP__ __NODE__ protein .
COMP:V-N(In) (treat,Hela)
SUBJ:V-N (treat,cell)
COMP:V-N(with) (treat,cycloheximide)
COMP:V-N(with) (treat,FMK)
COMP:V-N(with) (treat,overproduce)
OBJ:V-N (with,__NODE__)
MOD_ATT:N-ADJ (FMK,zVAD)
MOD_ATT:N-ADJ (overproduce,zVAD)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,Apo)
MOD_ATT:N-N (__SP__,agonist)
MOD_ATT:N-N (__SP__,anti)
MOD_ATT:N-N (Apo,__SP__)
MOD_ATT:N-N (antibody,[__NODE__])
MOD_ATT:N-N (antibody,protein)
COMP:N-N(in) (antibody,culture)
MOD_ATT:N-N (culture,cell)
SUBJ:V-N (increase,antibody)
COMP:V-N(in) (increase,manner)
MOD_ATT:N-N (manner,dose)
MOD_ATT:N-ADJ (manner,dependent)
COMP:N-N(of) (production,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)

Analyse 34

                  +-------------------COMP:V-N(with)------------------+                                                                                                                                                                                       
                  |                             +-----------------OBJ:V-N----------------+                                                                                                                                                                    
                  +------------COMP:V-N(with)------------+            |                  +---------------APPOS---------------+                           +------COMP:N-N(in)------+                                         +--------COMP:N-N(of)-------+     
      +COMP:V-N(In+                             |    +--MOD_ATT:N-ADJ-+                  |                 +-MOD_ATT:N-N+    |         +---MOD_ATT:N-N---+         +--MOD_ATT:N-N-+              +--MOD_ATT:N-N--+          |           +-MOD_ATT:N-ADJ-+     
      |    +SUBJ:V+-COMP:V-N(with)+             |    +MOD+            |          +MOD_ATT+                 |      +MOD_A+MOD_+         |        +MOD_ATT:+         |     +MOD_ATT:+              |      +MOD_ATT:+          |           |       +MOD_ATT+     
      |    |      |               |             |    |   |            |          |       |                 |      |     |    |         |        |        |         |     |        |              |      |        |          |           |       |       |     
 In Hela cells treated with cycloheximide and with zVAD FMK and overproducing __SP__ __NODE__ protein , agonist anti __SP__ Apo 1 [__NODE__] protein antibody in cell culture increases ( in a dose dependent manner ) production of __SP__ __NODE__ protein .
COMP:V-N(In) (treat,Hela)
SUBJ:V-N (treat,cell)
COMP:V-N(with) (treat,cycloheximide)
COMP:V-N(with) (treat,FMK)
COMP:V-N(with) (treat,overproduce)
OBJ:V-N (with,__NODE__)
MOD_ATT:N-ADJ (FMK,zVAD)
MOD_ATT:N-ADJ (overproduce,zVAD)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,Apo)
MOD_ATT:N-N (__SP__,agonist)
MOD_ATT:N-N (__SP__,anti)
MOD_ATT:N-N (Apo,__SP__)
MOD_ATT:N-N (antibody,[__NODE__])
MOD_ATT:N-N (antibody,protein)
COMP:N-N(in) (antibody,increase)
MOD_ATT:N-N (increase,cell)
MOD_ATT:N-N (increase,culture)
MOD_ATT:N-N (manner,dose)
MOD_ATT:N-N (manner,dependent)
COMP:N-N(of) (production,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)

Analyse 35

                  +-------------------COMP:V-N(with)------------------+                                                                                                                                                                                       
                  |                             +-----------------OBJ:V-N----------------+                                                                                                                                                                    
                  +------------COMP:V-N(with)------------+            |                  +---------------APPOS---------------+                           +------COMP:N-N(in)------+                                         +--------COMP:N-N(of)-------+     
      +COMP:V-N(In+                             |    +--MOD_ATT:N-ADJ-+                  |                 +-MOD_ATT:N-N+    |         +---MOD_ATT:N-N---+         +--MOD_ATT:N-N-+              +--MOD_ATT:N-N--+          |           +-MOD_ATT:N-ADJ-+     
      |    +SUBJ:V+-COMP:V-N(with)+             |    +MOD+            |          +MOD_ATT+                 |      +MOD_A+MOD_+         |        +MOD_ATT:+         |     +MOD_ATT:+              |      +MOD_ATT:+          |           |       +MOD_ATT+     
      |    |      |               |             |    |   |            |          |       |                 |      |     |    |         |        |        |         |     |        |              |      |        |          |           |       |       |     
 In Hela cells treated with cycloheximide and with zVAD FMK and overproducing __SP__ __NODE__ protein , agonist anti __SP__ Apo 1 [__NODE__] protein antibody in cell culture increases ( in a dose dependent manner ) production of __SP__ __NODE__ protein .
COMP:V-N(In) (treat,Hela)
SUBJ:V-N (treat,cell)
COMP:V-N(with) (treat,cycloheximide)
COMP:V-N(with) (treat,FMK)
COMP:V-N(with) (treat,overproduce)
OBJ:V-N (with,__NODE__)
MOD_ATT:N-ADJ (FMK,zVAD)
MOD_ATT:N-ADJ (overproduce,zVAD)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,Apo)
MOD_ATT:N-N (__SP__,agonist)
MOD_ATT:N-N (__SP__,anti)
MOD_ATT:N-N (Apo,__SP__)
MOD_ATT:N-N (antibody,[__NODE__])
MOD_ATT:N-N (antibody,protein)
COMP:N-N(in) (antibody,increase)
MOD_ATT:N-N (increase,cell)
MOD_ATT:N-N (increase,culture)
MOD_ATT:N-N (manner,dose)
MOD_ATT:N-ADJ (manner,dependent)
COMP:N-N(of) (production,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)

Analyse 36

                  +-------------------COMP:V-N(with)------------------+                                                                                                                                                                                       
                  |                             +-----------------OBJ:V-N----------------+---------------APPOS---------------+                           +------COMP:N-N(in)------+                                         +--------COMP:N-N(of)-------+     
      +COMP:V-N(In+------------COMP:V-N(with)------------+            |                  |                 +-MOD_ATT:N-N+    |         +---MOD_ATT:N-N---+         +--MOD_ATT:N-N-+              +--MOD_ATT:N-N--+          |           +-MOD_ATT:N-ADJ-+     
      |    +SUBJ:V+-COMP:V-N(with)+             |    +MOD+            |          +MOD_ATT+                 |      +MOD_A+MOD_+         |        +MOD_ATT:+         |     +MOD_ATT:+              |      +MOD_ATT:+          |           |       +MOD_ATT+     
      |    |      |               |             |    |   |            |          |       |                 |      |     |    |         |        |        |         |     |        |              |      |        |          |           |       |       |     
 In Hela cells treated with cycloheximide and with zVAD FMK and overproducing __SP__ __NODE__ protein , agonist anti __SP__ Apo 1 [__NODE__] protein antibody in cell culture increases ( in a dose dependent manner ) production of __SP__ __NODE__ protein .
COMP:V-N(In) (treat,Hela)
SUBJ:V-N (treat,cell)
COMP:V-N(with) (treat,cycloheximide)
COMP:V-N(with) (treat,FMK)
COMP:V-N(with) (treat,overproduce)
OBJ:V-N (with,__NODE__)
MOD_ATT:N-ADJ (FMK,zVAD)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,Apo)
MOD_ATT:N-N (__SP__,agonist)
MOD_ATT:N-N (__SP__,anti)
MOD_ATT:N-N (Apo,__SP__)
MOD_ATT:N-N (antibody,[__NODE__])
MOD_ATT:N-N (antibody,protein)
COMP:N-N(in) (antibody,increase)
MOD_ATT:N-N (increase,cell)
MOD_ATT:N-N (increase,culture)
MOD_ATT:N-N (manner,dose)
MOD_ATT:N-ADJ (manner,dependent)
COMP:N-N(of) (production,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)